Orca is developing RORγ inhibitors for the treatment of autoimmune disease

Orca Pharmaceuticals Is a company based in Oxford UK developing oral drugs for the treatment of chronic inflammatory disease.  Based on the pioneering work of Professor Dan Littman, we have a medicinal chemistry programme producing orally available inhibitors of a nuclear hormone receptor found in a class of white blood cell involved in autoimmune disease.  These pathological pathways are already validated in man by monoclonal antibodies, though the target selected by Orca offers considerable therapeutic benefits and the company is focussed on establishing human proof of concept by 2016.